Assays for Gene Amplification

State of the Art, Pitfalls, and Promises
  • Chungyeul Kim
  • Yongkuk Song
  • Soonmyung Paik
Part of the Cancer Drug Discovery and Development book series (CDD&D)


Since the approval of trastuzumab for the treatment of HER2-positive breast cancer (1), there has been an active debate as to the reproducibility and validity of the FDA-approved assays that detect HER2 abnormalities in the tumor tissue. In this chapter, various clinical assays are compared focusing on practical issues.

Key Words

Gene amplification trastuzumab HER-2 testing breast cancer 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Slamon DJ, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overex presses HER2. N Engl J Med 2001;344:783–792.PubMedCrossRefGoogle Scholar
  2. 2.
    Pollack JR, et al. Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proc Natl Acad Sci USA 2002;99:12963–12968.PubMedCrossRefGoogle Scholar
  3. 3.
    Hyman E, et al. Impact of DNA amplification on gene expression patterns in breast cancer. Cancer Res 2002;62:6240–6245.PubMedGoogle Scholar
  4. 4.
    Slamon DJ, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177–182.PubMedCrossRefGoogle Scholar
  5. 5.
    Jarvinen TA, Liu ET. HER-2/neu and topoisomerase IIalpha in breast cancer. Breast Cancer Res Treat 2003;78:299–311.PubMedCrossRefGoogle Scholar
  6. 6.
    Niehans GA, et al. Stability of HER-2/neu expression over time and at multiple metastatic sites. J Natl Cancer Inst 1993;85:1230–1235.PubMedCrossRefGoogle Scholar
  7. 7.
    Masood S, Bui MM. Assessment of Her-2/neu overexpression in primary breast cancers and their metastatic lesions: an immunohistochemical study. Ann Clin Lab Sci 2000;30:259–265.PubMedGoogle Scholar
  8. 8.
    Simon R, et al. Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer. J Natl Cancer Inst 2001;93:1141–1146.PubMedCrossRefGoogle Scholar
  9. 9.
    Vogel CL, et al. First-line Trastuzumab monotherapy in metastatic breast cancer. Oncology 2001;61(Suppl 2):37–42.PubMedCrossRefGoogle Scholar
  10. 10.
    Dowsett M, et al. Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres. J Pathol 2003;199:418–423.PubMedCrossRefGoogle Scholar
  11. 11.
    Paik S, et al. Real-world performance of HER2 testing—National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst 2002;94:852–854.PubMedGoogle Scholar
  12. 12.
    Roche PC, et al. Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst 2002;94:855–857.PubMedGoogle Scholar
  13. 13.
    Andersen CL, et al. Improved procedure for fluorescence in situ hybridization on tissue microarrays. Cytometry 2001;45:83–86.PubMedCrossRefGoogle Scholar
  14. 14.
    Tanner M, et al. Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am J Pathol 2000;157:1467–1472.PubMedGoogle Scholar
  15. 15.
    Gupta D, et al. Comparison of fluorescence and chromogenic in situ hybridization for detection of HER-2/neu oncogene in breast cancer. Am J Clin Pathol 2003;119:381–387.PubMedCrossRefGoogle Scholar
  16. 16.
    Millson A, et al. Comparison of two quantitative polymerase chain reaction methods for detecting HER2/neu amplification. J Mol Diagn 2003;5:184–190.PubMedGoogle Scholar
  17. 17.
    Isola J, et al. Genetic alterations in ERBB2-amplified breast carcinomas. Clin Cancer Res 1999;5:4140–4145.PubMedGoogle Scholar

Copyright information

© Humana Press Inc., Totowa, NJ 2006

Authors and Affiliations

  • Chungyeul Kim
    • 1
  • Yongkuk Song
    • 1
  • Soonmyung Paik
    • 1
  1. 1.Division of PathologyNational Surgical Adjuvant Breast and Bowel Project FoundationPittsburghUSA

Personalised recommendations